Skip to main content
SpringerLink
Log in

Myocardial Viability

  • Chapter
  • First Online:
Atlas of Nuclear Cardiology

  • 830 Accesses

Abstract

Heart failure (HF) is evolving as an enormous cardiovascular health problem worldwide. In the United States alone, more than five million patients suffer from symptomatic disease, and more than half a million patients are newly diagnosed with HF every year. There are at least one million hospitalizations that result in 6.5 million hospital days and nearly 300,000 deaths each year. The total inpatient and outpatient costs for HF are approximately $35 billion. Two thirds of the heart failure is secondary to coronary artery disease, and not infrequently assessment of myocardial viability becomes necessary for appropriate management of these patients by non-surgical and surgical revascularization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Taegtmeyer H, Sharma S, Golfman L, et al. Linking gene expression to function: metabolic flexibility in normal and diseased heart. Ann N Y Acad Sci. 2004;1015:1–12.

    Article  Google Scholar 

  2. Depre C, Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res. 2000;45:538–48.

    Article  CAS  Google Scholar 

  3. Kim HD, Kim DJ, Lee IJ, et al. Human fetal heart development after mid-term: morphometry and ultrastructural study. J Mol Cell Cardiol. 1992;24:949–65.

    Article  CAS  Google Scholar 

  4. Narula J, Young JB. Pathogenesis of heart failure: the penultimate survival instinct? Heart Fail Clin. 2005;1:xi–xii.

    Google Scholar 

  5. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–9.

    Article  CAS  Google Scholar 

  6. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 1999;96:8144–9.

    Article  CAS  Google Scholar 

  7. Narula N, Narula J, Zhang PJ, Haider N, Raghunath PN, Brittin R, et al. Is the myofibrillarlytic myocyte a forme fruste apoptotic myocyte? Ann Thorac Surg. 2005;79:1333–7; discussion 1337.

    Article  Google Scholar 

  8. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation. 1999;99:2757–64.

    Article  CAS  Google Scholar 

  9. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30–7.

    Article  Google Scholar 

  10. Zhao MJ, Zhang H, Robinson TF, Factor SM, Sonnenblick EH, Eng C. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunction (“stunned”) but viable myocardium. J Am Coll Cardiol. 1987;10:1322–34.

    Article  CAS  Google Scholar 

  11. Shirani J, Lee J, Quigg RJ, Pick R, Bacharach SL, Dilsizian V. Relation of thallium uptake to morphologic features of chronic ischemic heart disease: evidence for myocardial remodeling in non-infarct myocardium. J Am Coll Cardiol. 2001;38:84–90.

    Article  CAS  Google Scholar 

  12. Taegtmeyer H. Modulation of responses to myocardial ischemia: metabolic features of myocardial stunning, hibernation, and ischemic preconditioning. In: Dilsizian V, editor. Myocardial viability: a clinical and scientific treatise. Armonk: Futura; 2000. p. 25–36.

    Google Scholar 

  13. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331–6.

    Article  Google Scholar 

  14. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68:785–95.

    Article  CAS  Google Scholar 

  15. Bonow RO, Dilsizian V. Thallium-201 for assessment of myocardial viability. Sem Nucl Med. 1991;21:230–41.

    Article  CAS  Google Scholar 

  16. Elefteriades JA, Tolis G Jr, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411–7.

    Article  CAS  Google Scholar 

  17. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72(Suppl V):V123–35.

    CAS  PubMed  Google Scholar 

  18. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–9.

    Article  CAS  Google Scholar 

  19. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379(9814):453–60.

    Article  Google Scholar 

  20. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978–85.

    Article  CAS  Google Scholar 

  21. Matsuzaki M, Gallagher KP, Kemper S, White F, Ross J Jr. Sustained regional dysfunction produced by prolonged coronary stenosis: gradual recovery after reperfusion. Circulation. 1983;68:170–82.

    Article  CAS  Google Scholar 

  22. Arnado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R, et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol. 2004;44:2383–9.

    Article  Google Scholar 

  23. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105:162–7.

    Article  Google Scholar 

  24. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53.

    Article  CAS  Google Scholar 

  25. Perrone-Filardi P, Pace L, Prastaro M, Squame F, Betocchi S, Soricelli A, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation. 1996;94:2712–9.

    Article  CAS  Google Scholar 

  26. Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mild-to-moderate irreversible thallium defects: are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation. 1998;98:501–8.

    Article  CAS  Google Scholar 

  27. Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med. 1990;323:141–6.

    Article  CAS  Google Scholar 

  28. Dilsizian V. Cardiac magnetic resonance versus SPECT: are all non-infarct myocardial regions created equal? J Nucl Cardiol. 2007;14:9–14.

    Article  Google Scholar 

  29. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8.

    Article  Google Scholar 

  30. Hunt SA, Baker DW, Chin MH. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol. 2001;38:2101–13.

    Article  CAS  Google Scholar 

  31. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003;108:1404–18.

    Google Scholar 

  32. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al.; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary artery disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002–12.

    Google Scholar 

  33. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, de Kemp R, et al.; PARR-2 Investigators. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2:1060–8.

    Google Scholar 

  34. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al.; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617–25.

    Google Scholar 

  35. Dilsizian V, Bacharach SL, Beanlands SR, Bergmann SR, Delbeke D, Fischman AJ, et al. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16:651. https://doi.org/10.1007/s12350-009-9094-9.

    Article  Google Scholar 

  36. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–48.

    Article  Google Scholar 

  37. Narula J, Dawson MS, Singh BK, Amanullah A, Acio ER, Chaudhry FA, et al. Noninvasive characterization of stunned, hibernating, remodeled and nonviable myocardium in ischemic cardiomyopathy. J Am Coll Cardiol. 2000;36:1913–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Maryland School of Medicine, Baltimore, MD, USA

    Vasken Dilsizian

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jagat Narula

Authors
  1. Vasken Dilsizian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jagat Narula
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jagat Narula .

Editor information

Editors and Affiliations

  1. University of Maryland School of Medicine, Baltimore, MD, USA

    Vasken Dilsizian

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jagat Narula

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dilsizian, V., Narula, J. (2021). Myocardial Viability. In: Dilsizian, V., Narula, J. (eds) Atlas of Nuclear Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-49885-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49885-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-49884-9

  • Online ISBN: 978-3-030-49885-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation